National Institutes of Health
Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)
What it funds
The purpose of this notice of funding opportunity (NOFO) is to support research and/or preclinical development of highly efficacious vaccines against malaria - one of the deadliest mosquito-borne diseases - by capitalizing on recent technological innovations, particularly in structure-based immunogen design, improved formulations, and combination vaccines. The goal is to achieve long-lasting, highly effective protection that can save lives, strengthen public health security in the United States, and serve as a model for, or are potentially effective against, other mosquito-borne diseases.
Who can apply
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibilityForeign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/s
How to apply
Read the full notice and application package on the official listing, RFA-AI-28-024 on Grants.gov. Questions go to MalariaandOtherMosquitoBorneDiseases@mail.nih.gov. Make sure your SAM.gov registration and Grants.gov or agency portal accounts are active well before the deadline, since registration can take several weeks.
Last updated by the agency Oct 12, 2026. Tracked by Federal Runway since Nov 17, 2026. Confirm details on the official notice.